Publication | Closed Access
Serial Bone Scanning Using Technetium 99m Diphosphonate in Patients Undergoing Cyclical Combination Chemotherapy for Advanced Breast Cancer
39
Citations
0
References
1976
Year
Uptake MeasurementsOncologic ImagingSpinal OncologyOsteoporosisScanning AgentBone DiseaseAdvanced Breast CancerRadiation MedicineOncologyMetronomic TherapyBreast ImagingRadiopharmaceutical TherapyClinical Radiation OncologyRadiation OncologyMolecular ImagingCancer ResearchNuclear MedicineMolecular OncologyRadiologyHealth SciencesMedical ImagingRadiological SciencesRadiologic ImagingBone ImagingBreast CancerSerial Bone ScansMedicine
Serial bone scans and uptake measurements with 99mTc labeled diphosphonate were performed on patients with osseous metastases from primary breast cancer. Eleven of 18 patients showed a transient worsening of the scan appearance shortly after cyclical combination chemotherapy was commenced. The appearance of this “flare” effect could not be correlated significantly with the patients' response to treatment. It is stressed that an apparently deteriorating 99mTc diphosphonate bone scan is not an adequate basis on which to terminate a particular therapeutic regime. We have previously reported similar results for a series in which 87mSr was the scanning agent.